Showing 5391-5400 of 10820 results for "".
- Cassiopea Submits NDA for New Acne Treatmenthttps://practicaldermatology.com/news/cassiopea-submits-nda-for-new-acne-treatment/2460131/Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for th
- Blocking LSD1 May Thwart Common Skin Cancer Growthhttps://practicaldermatology.com/news/blocking-lsd1-may-thwart-common-skin-cancer-growth/2460130/The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. A new study from researchers in the Perelman School of Medicine at the University of Pennsylvania has now identifie
- Study Shows StrataGraft-treated Deep Partial-thickness Burns Did Not Require Surgical Harvest of Healthy Skinhttps://practicaldermatology.com/news/study-shows-stratagraft-treated-deep-partial-thickness-burns-did-not-require-surgical-harvest-of-healthy-skin/2460127/Mallinckrodt plc shared results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries (ISBI). Study data showed that treatment with a single application of StrataGraft tissue resulted in
- Complete Wound Healing Seen on Index Lesion of the First Subject in an Ongoing Phase 2 Trial of RGN-137 Dermal Gel for EBhttps://practicaldermatology.com/news/complete-wound-healing-seen-on-index-lesion-of-the-first-subject-in-an-ongoing-phase-2-trial-of-rgn-137-dermal-gel-for-eb/2460118/Lenus Therapeutics, LLC, a US-based joint venture between GtreeBNT and Yuyang DNU in Korea, has confirmed complete wound healing of the index lesion of the first subject enrolled in its ongoing single-masked Phase 2 clinical trial with RGN-137 dermal gel for Epidermolysis Bullosa (EB).
- Foamix Submits NDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosaceahttps://practicaldermatology.com/news/foamix-submits-nda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea/2460117/Foamix Pharmaceuticals Ltd. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older
- Summer AAD News: Dramatic Spike in Female Skin Cancer Linked to Tanninghttps://practicaldermatology.com/news/summer-aad-news-dramatic-spike-in-female-skin-cancer-linked-to-tanning/2460105/Skin cancer in women is on the rise, and indoor tanning may be to blame, according to new research presented at the 2019 American Academy of Dermatology Summer Meeting in New York City. Between 1970 and 2009, rates of melanoma increased 800 percent among women ages 18-39, making it the
- Proof of Concept Study Supports Dermata’s Topical Delivery Mechanism for Botulinum Toxinhttps://practicaldermatology.com/news/proof-of-concept-study-supports-dermatas-topical-delivery-mechanism-for-botulinum-toxin/2460089/Dermata Therapeutics’ DMT410 (DMT310 + botulinum toxin) performed well in a Phase 1proof of concept study for the treatment of primary axillary hyperhidrosis, the Company reports. DMT410 is a combination regimen for the treatment of skin
- Meet truSculpt flex: Cutera’s Solution for Toned Abs, Butts and Thighshttps://practicaldermatology.com/news/meet-trusculpt-flex-cuteras-solution-for-toned-abs-butts-and-thighs/2460084/Cutera is launching the new truSculpt flex, muscle sculpting platform in the United States, and commercial shipments are slated to begin immediately. truSculpt flex is FDA-cleared for the indications of the improvement of abdominal tone, strengt
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Der
- Study: Indoor Tanning Addiction May Be Abetted by Genetic and Psychiatric Factorshttps://practicaldermatology.com/news/study-indoor-tanning-addiction-may-be-abetted-by-genetic-and-psychiatric-factors/2460059/A combination of elevated symptoms of depression along with modifications in a gene responsible for dopamine activity appear to influence an addiction to indoor tanning in young, white non-Hispanic women, a new study suggests. The findings appear in the Annals of Behaviora